CN112494421A - Slow-release soluble microneedle, preparation method and application - Google Patents
Slow-release soluble microneedle, preparation method and application Download PDFInfo
- Publication number
- CN112494421A CN112494421A CN202011539854.9A CN202011539854A CN112494421A CN 112494421 A CN112494421 A CN 112494421A CN 202011539854 A CN202011539854 A CN 202011539854A CN 112494421 A CN112494421 A CN 112494421A
- Authority
- CN
- China
- Prior art keywords
- drug
- microneedle
- polymer
- carrier
- slowly released
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Medical Informatics (AREA)
- Ceramic Engineering (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a sustained-release soluble microneedle, a preparation method and application. The micro-needle comprises a substrate, a needle body and a carrier which is distributed in the needle body and is coated with a drug to be slowly released, wherein the carrier comprises a degradable high molecular material or inorganic nano-particles modified by a polymer. The method comprises the following steps: preparing a carrier coated with a drug to be slowly released by adopting one of an emulsion method, a dialysis method, a solvent volatilization method, a spray drying method and a polyelectrolyte protection method; the carrier comprises degradable high molecular materials or inorganic nanoparticles; dissolving or dispersing the carrier coated with the drug to be slowly released in a matrix solution, casting the matrix solution into a mold by a vacuum pumping method, drying and demolding to obtain the slowly released soluble microneedle. The invention slows down the release speed of the drug by taking the degradable high molecular material or the inorganic nano particles modified by the polymer as the carrier of the drug.
Description
Technical Field
The invention belongs to the field of microneedles, and particularly relates to a sustained-release soluble microneedle, a preparation method and application.
Background
When the microneedle is used for local administration on the skin, the microneedle can effectively pierce the stratum corneum of the skin and cannot touch nerves, so that adverse reactions caused by the drugs passing through the gastrointestinal tract are avoided, pain is not caused, the bioavailability of the drugs is increased, and the compliance of patients is improved. The micro-needles are of various types, and comprise hollow micro-needles and solid micro-needles, and the solid micro-needles are divided into tissue pretreatment micro-needles, soluble drug-carrying micro-needles and insoluble drug-coating micro-needles. The soluble microneedle constructed by the polymer material with good biocompatibility and in-vivo solubility has the advantages of simple preparation method, high drug loading capacity and high safety. However, when the drug-loaded dissolvable microneedle is locally used on the skin, the microneedle substrate can be quickly dissolved in the skin, so that the drug can be quickly released and absorbed by a large amount of partial blood vessels, a stable drug concentration can not be maintained locally on the skin, toxic and side effects can be brought, and the bioavailability of the drug is greatly reduced.
Disclosure of Invention
Aiming at the defects or the improvement requirements of the prior art, the invention provides a sustained-release soluble microneedle, a preparation method and application, aiming at reducing the release speed of a drug by using a degradable high molecular material or inorganic nanoparticles modified by a polymer as a carrier of the drug, thereby solving the technical problem that in the prior art, a microneedle matrix can be rapidly dissolved in skin, so that the drug is rapidly released and is absorbed by partial blood vessels in large quantity.
In order to achieve the above objects, according to one aspect of the present invention, there is provided a sustained release soluble microneedle, including a base, a needle body, and a carrier distributed in the needle body and coated with a drug to be sustained released, wherein the carrier includes a degradable polymer material or polymer-modified inorganic nanoparticles.
Preferably, the carrier coated with the drug to be slowly released is one or more of microspheres, microcapsules, nanoparticles, liposomes, micelles and slow release membranes.
Preferably, the inorganic nanoparticles comprise one of a nanocarbon material, gold nanoparticles, quantum dots, magnetic nanoparticles, hollow mesoporous silica, the polymer is a biodegradable and positively charged polymer, and preferably, the biodegradable and positively charged polymer is one of chitosan, polydopamine, polyetherimide, and poly N, N-dimethylaminoethyl methacrylate.
Preferably, the degradable polymer material includes a natural biodegradable polymer material, a semi-synthetic biodegradable polymer material or a synthetic biodegradable polymer material.
Preferably, the natural biodegradable high molecular material comprises gelatin, chitosan, sodium alginate, starch or cellulose; the semi-synthetic biodegradable high polymer material comprises carboxymethyl cellulose, methyl cellulose or cellulose acetate; the synthetic biodegradable high molecular material comprises aliphatic polyester polymer, polycarbonate polymer, polyanhydride or poly alpha-amino acid polymer or block polymer. For example, polylactic-co-glycolic acid (PLGA), polypropylene carbonate, polysebacic anhydride, polyserine, poly epsilon-caprolactone-polyethylene glycol copolymer (PCL-PEG), polyethylene glycol-polylactic acid, and the like.
Preferably, the polymer adopted by the substrate and the needle body comprises one or more of hyaluronic acid, chondroitin sulfate, sodium alginate, amylopectin, hydroxypropyl-beta-cyclodextrin and gelatin.
Preferably, the size of the carrier coated with the drug to be slowly released is 50-5000 nanometers, and the content of the drug to be slowly released coated in the slowly released soluble microneedle is 20-2000 micrograms.
Preferably, the length of the needle body of the slow release soluble microneedle is 200-1000 microns, the shape of the needle body is a triangular cone or a cone,
according to another aspect of the present invention, there is provided a method of preparing the sustained-release soluble microneedle described above, comprising the steps of:
(1) preparing a carrier coated with a drug to be slowly released by adopting one of an emulsion method, a dialysis method, a solvent volatilization method, a spray drying method and a polyelectrolyte protection method; the carrier comprises degradable high molecular materials or inorganic nanoparticles;
(2) dissolving or dispersing the carrier coated with the drug to be slowly released in a matrix solution, casting the matrix solution into a mold by a vacuum pumping method, drying and demolding to obtain the slowly released soluble microneedle.
Preferably, the polyelectrolyte protection method specifically comprises:
dissolving the hollow mesoporous silica nanoparticles and the drug to be slowly released in dimethyl sulfoxide, uniformly stirring, and removing the dimethyl sulfoxide by using a negative pressure method to obtain hollow mesoporous silica nanoparticles loaded with the drug to be slowly released;
dispersing the hollow mesoporous silica nano particles loaded with the drug to be slowly released in a biodegradable polymer with positive electricity, stirring, centrifuging and washing to obtain the carrier coated with the drug to be slowly released.
When the hollow mesoporous silica nanoparticles loaded with the drug to be slowly released are dispersed in the chitosan solution, as a preferable scheme, the concentration of the chitosan is 0.1-2% (mass-to-volume ratio), and the mass ratio of the hollow mesoporous silica nanoparticles loaded with the drug to be slowly released to the chitosan is 1 (1-4). The concentration and the mass ratio are strictly controlled, so that the maximum adsorption of the chitosan can be realized, and the carrier coated with the drug to be slowly released with the best performance can be obtained.
Wherein, when the carrier coated with the medicament to be slowly released is prepared by adopting an emulsion method, a dialysis method, a solvent volatilization method and a spray drying method, different medicament-carrying quantities can be obtained by adjusting the concentration of the polymer.
According to a further aspect of the present invention, there is provided a use of the sustained release soluble microneedle described above for sustained release of methotrexate, wherein the drug to be sustained released in the microneedle is methotrexate.
In general, at least the following advantages can be obtained by the above technical solution contemplated by the present invention compared to the prior art.
(1) The slow-release soluble microneedle provided by the invention can be used for coating the drug to be slow-released by taking the degradable high molecular material or the polymer-modified inorganic nanoparticles as the drug carrier, so that the release speed of the coated drug can be effectively slowed down. The drug carrier can stay at the local part of the skin and slowly release the drug after the needle tip is dissolved, so that the concentration of the drug in the skin can be kept within a specific concentration range within a period of time, and a series of problems of low drug utilization efficiency, large side effect, frequent drug administration and the like caused by the direct and rapid drug release of the soluble microneedle in the skin are solved.
(2) According to the invention, the degradable high polymer material is used as a carrier to coat the drug to be slowly released, so that the release speed of the drug is limited by the dissolution speed of the degradable high polymer material, and the slow release of the drug is realized.
(3) According to the invention, the inorganic nanoparticles modified by the polymer are used as a carrier to coat the drug to be slowly released, for example, the biodegradable and positively charged polymer modified hollow mesoporous silica is used for loading the drug in the holes of the hollow mesoporous silica, and the biodegradable and positively charged polymer is adsorbed on the surface of the drug loaded hollow mesoporous silica through electrostatic adsorption because the hollow mesoporous silica is negatively charged, so that the drug is coated, and the rapid release of the drug is prevented.
Drawings
FIG. 1 is a transmission electron micrograph of a methotrexate drug carrier in example 5 of the present invention;
FIG. 2 is a graph showing the particle size distribution of the methotrexate drug carrier in example 5 of the present invention;
fig. 3A is a scanning electron micrograph of a sustained-release soluble microneedle prepared by example 5 of the present invention;
fig. 3B is a partial enlarged view of the extended release soluble microneedle of fig. 3A;
FIG. 4 is a graph showing in vitro release of hollow mesoporous silica nanoparticles loaded with methotrexate and a methotrexate-loaded drug carrier, which are prepared by example 5 of the present invention;
FIG. 5 is a graph of ear thickness variation for different groups of mice in characterization example 2 of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is described in further detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention. In addition, the technical features involved in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
Example 1
The embodiment provides a preparation method of a sustained-release soluble microneedle, which specifically comprises the following steps:
(1) preparing the carrier coated with the methotrexate drug by a spray drying method: dissolving chitosan powder and methotrexate in 0.2% hydrochloric acid water solution, spraying into a dryer for drying after complete dissolution, and collecting the prepared methotrexate chitosan drug carrier.
(2) Preparing a microneedle mould: uniformly stirring polydimethylsiloxane raw material (PDMS, Sylgard 184) and a curing agent according to a mass ratio of 10:1, vacuumizing to remove bubbles, casting the liquid polydimethylsiloxane containing the curing agent into a plastic culture dish containing a polymethacrylic acid microneedle positive membrane (the length of a needle point of the positive membrane is 850 microns), heating for 2 hours at 80 ℃, after the PDMS is cured, carefully separating the microneedle positive membrane from the PDMS to obtain a microneedle PDMS mold, and carrying out plasma treatment on the PDMS microneedle mold for later use.
(3) Hyaluronic acid powder was dissolved in water at a concentration of 200mg/mL, and the solution was stirred overnight at room temperature to completely dissolve the hyaluronic acid powder.
(4) The prepared methotrexate chitosan drug carrier particles are dissolved or dispersed in a hyaluronic acid solution, and are carefully stirred to be uniformly dispersed to obtain a dispersion liquid.
(5) And (3) casting the dispersion into a PDMS microneedle mould, vacuumizing to enable the dispersion to fill the microneedle mould as much as possible, scraping off redundant solution on the surface of the mould, repeating the steps for three times to enable the methotrexate chitosan drug carrier to be gathered at the needle point of the mould, and finally casting the solution to form the microneedle substrate. And (3) putting the microneedle mould filled with the solution into a dryer overnight, and after drying, carefully demoulding the microneedle to obtain the microneedle patch loaded with the methotrexate chitosan drug carrier.
Example 2
The embodiment provides a preparation method of a sustained-release soluble microneedle, which specifically comprises the following steps:
(1) solvent volatilization method for preparing methotrexate drug carrier: dissolving a certain amount of polylactic-co-glycolic acid (PLGA) in dichloromethane, adding a proper amount of methotrexate to disperse uniformly, pouring into 1% polyvinyl alcohol (PVA) solution, stirring at high speed for 3 minutes at room temperature to form O/W emulsion, then continuously and slowly stirring at room temperature for 4 hours to volatilize the organic solvent, and washing and centrifuging to obtain the methotrexate drug carrier.
(2) Preparing a microneedle mould: uniformly stirring polydimethylsiloxane raw materials and a curing agent according to a mass ratio of 10:1, vacuumizing to remove bubbles, casting liquid polydimethylsiloxane containing the curing agent into a plastic culture dish containing a polymethacrylic acid microneedle positive membrane (the length of a needle point of the positive membrane is 650 microns), heating for 2 hours at 80 ℃, after curing PDMS, carefully separating the microneedle positive membrane from PDMS to obtain a PDMS microneedle mould, and carrying out plasma treatment on the PDMS microneedle mould for later use.
(3) Dissolving beta-cyclodextrin powder in water at a concentration of 100mg/mL, and stirring overnight in a water bath at 60 ℃ to completely dissolve the beta-cyclodextrin powder to obtain the microneedle matrix solution.
(4) And dispersing the prepared methotrexate drug carrier in a microneedle matrix solution to obtain a dispersion liquid.
(5) The dispersion was cast into a PDMS mold, and the use of centrifugation allowed the solution to completely fill the needle tip portion, with some aggregation of the methotrexate drug carrier at the needle tip portion due to the centrifugation. And (3) placing the microneedle patch in a dryer overnight, and after drying, carefully demoulding the microneedle to obtain the microneedle patch loaded with the methotrexate drug carrier.
Example 3
The embodiment provides a preparation method of a sustained-release soluble microneedle, which specifically comprises the following steps:
(1) solvent volatilization method for preparing methotrexate drug carrier: weighing 20mg of poly-epsilon-caprolactone-polyethylene glycol copolymer (PCL-PEG) and 4mg of methotrexate, dissolving in 10mL of dimethylformamide, slowly dripping the solution into deionized water under the condition of stirring, continuously stirring for ten minutes, dialyzing, washing after 24 hours of dialysis, and centrifuging to obtain the methotrexate drug carrier.
(2) Preparing a microneedle mould: uniformly stirring polydimethylsiloxane raw materials and a curing agent according to a mass ratio of 10:1, vacuumizing to remove bubbles, casting liquid polydimethylsiloxane containing the curing agent into a plastic culture dish containing a polymethacrylic acid microneedle positive membrane (the length of a needle point of the positive membrane is 650 microns), heating for 2 hours at 80 ℃, after curing the PDMS, carefully separating the microneedle positive membrane from the PDMS to obtain a PDMS microneedle mould, and carrying out plasma treatment on the PDMS microneedle mould for later use.
(3) The dextran powder was dissolved in water at a concentration of 150mg/mL, stirred well and the solution was bubbled out. And dispersing the prepared methotrexate drug carrier into a glucan solution, and uniformly mixing.
(4) And (3) casting the solution into a prepared PDMS mold, using vacuum and centrifugation in a matching manner to enable the solution to completely fill the needle point of the mold, putting the mold into a dryer, drying overnight, taking out, and carefully peeling off the microneedle patch to obtain the microneedle patch loaded with the methotrexate drug carrier.
Example 4
The embodiment provides a preparation method of a sustained-release soluble microneedle, which specifically comprises the following steps:
(1) the double emulsion method is used for preparing the methotrexate drug carrier: firstly, the medicine methotrexate is dissolved in 0.4 percent sodium hydroxide solution to prepare a methotrexate sodium salt solution which is used as an internal water phase. Dissolving polyethylene glycol-polylactic acid in dichloromethane, stirring until the polyethylene glycol-polylactic acid is completely dissolved to be used as an oil phase, adding the internal water phase into the oil phase under a certain oil-water ratio, performing ultrasonic emulsification by using a probe type ultrasonic machine to obtain a stable primary emulsion, and then adding the primary emulsion into a certain volume of polyvinyl alcohol solution containing 0.6% to be stirred to obtain a double emulsion. The double emulsion is placed in a room with a constant temperature of 30 ℃ overnight, and after dichloromethane in the double emulsion is completely volatilized, the medicine carrier coated with the methotrexate can be obtained by centrifugation and washing.
(2) Preparing a microneedle mould: uniformly stirring polydimethylsiloxane raw materials and a curing agent according to the mass ratio of 10:1, vacuumizing to remove bubbles, pouring liquid polydimethylsiloxane containing the curing agent into a plastic culture dish with a polymethacrylic acid microneedle positive membrane, heating at 80 ℃ for 2 hours, after curing PDMS, carefully separating the microneedle positive membrane from PDMS to obtain a PDMS microneedle mould, and carrying out plasma treatment on the PDMS microneedle mould for later use.
(3) Dissolving chitosan powder in 1% acetic acid solution, stirring overnight, and taking the solution as microneedle matrix solution after complete dissolution. And dispersing the carrier carrying the methotrexate prepared in the step into a microneedle substrate solution.
(4) And (3) casting the solution into a PDMS mold, vacuumizing to enable the solution to fill the microneedle mold as much as possible, scraping off redundant solution on the surface of the mold, repeating the steps for three times to enable the methotrexate drug carrier to be gathered at the needle point of the mold, and finally casting the solution to form the microneedle substrate. And (3) putting the microneedle mould filled with the solution into a dryer overnight, and after drying, carefully demoulding the microneedle to obtain the microneedle patch loaded with the methotrexate drug carrier.
Example 5:
the embodiment provides a preparation method of a sustained-release soluble microneedle, which specifically comprises the following steps:
1. preparing a methotrexate drug carrier by a polyelectrolyte protection method:
(1) firstly, dissolving the prepared Hollow Mesoporous Silica Nanoparticles (HMSN) and the methotrexate drug in dimethyl sulfoxide (DMSO) and stirring overnight, and removing the DMSO solvent by using a negative pressure method to obtain the hollow mesoporous silica nanoparticles (marked as MTX @ HMSN) loaded with the methotrexate drug.
(2) Dissolving the hollow mesoporous silica nanoparticle MTX @ HMSN loaded with the methotrexate drug into a prepared 0.6% chitosan solution, stirring for 3 hours at the temperature of 30 ℃, and coating chitosan molecules on the surfaces of the MTX @ HMSN nanoparticles through electrostatic interaction. The obtained solution is centrifuged and washed for 3 times to obtain the methotrexate-loaded drug carrier (as MTX @ HMSN/CS). As shown in figure 1, is a transmission electron micrograph of the methotrexate drug carrier. As shown in figure 2, the particle size distribution diagram of the methotrexate drug carrier is shown, and the average particle size of the drug carrier is 464.8 +/-45.31 nm.
2. Preparing a microneedle mould: uniformly stirring polydimethylsiloxane raw materials and a curing agent according to the mass ratio of 10:1, vacuumizing to remove bubbles, casting the liquid polydimethylsiloxane containing the curing agent into a plastic culture dish containing a polymethacrylic acid microneedle positive membrane (the length of a needle point of the positive membrane is 850 mu m), heating for 2 hours at 80 ℃, after curing PDMS, carefully separating the microneedle positive membrane from the PDMS to obtain a PDMS microneedle mould, and carrying out plasma treatment on the PDMS mould for later use.
3. The chondroitin sulfate was dissolved in water, stirred overnight in the dark to be completely dissolved as a microneedle matrix solution, and the MTX @ HMSN/CS obtained in the above step was dispersed in the microneedle matrix solution.
4. The solution is cast into a PDMS mold, the microneedle mold can be filled with the solution as much as possible by a vacuum pumping method, the surface redundant solution is removed by a scraper, and the microneedle mold is placed into a dryer for drying for 24 hours. And after the needle point is completely dried, continuously casting a layer of PVP/PVA (1: 1) solution on the surface of the mould, and continuously putting the mould into a drying oven for drying for 24 hours to form the microneedle substrate layer. After drying, the microneedle is carefully demoulded, and the microneedle patch loaded with the MTX @ HMSN/CS can be obtained. Fig. 3A and 3B are scanning electron micrographs of the microneedle patch and a partial enlarged view thereof.
Characterization example 1
The hollow mesoporous silica nanoparticles MTX @ HMSN loaded with the drug methotrexate and the drug carrier MTX @ HMSN/CS loaded with the drug methotrexate, which were prepared in example 5, were dissolved in 2mL of phosphate buffer solution (PBS, pH 7.4), and then the mixture was put into a centrifuge tube with a cover, incubated in a shaker at 37 degrees celsius and an oscillation speed of 200 rpm for fourteen days, and at appropriate time intervals, the centrifuge tube was removed and centrifuged to collect the whole supernatant, 2mL of fresh PBS was added, and the collected sample was subjected to uv detection. As shown in FIG. 4, which is an in vitro release diagram of MTX @ HMSN/CS and MTX @ HMSN, it can be seen that MTX @ HMSN coated with chitosan molecule has the ability to slowly release methotrexate.
Characterization example 2
The left ear of the mouse was induced to develop psoriatic dermatitis to establish a psoriasis mouse model. The mice were randomly divided into seven groups of five mice each, which were a control group (no treatment), a disease group, a blank microneedle group, a blank carrier microneedle group, an oral administration group, a methotrexate drug carrier microneedle group (experimental group), and a low-dose methotrexate microneedle group. Keeping the total drug dose of each group consistent, the microneedle treatment was performed every three days, and the low-dose methotrexate microneedle group was performed once a day (the experiment was performed for seven days in total). For example, fig. 5 is a graph of the variation of ear thickness of mice in different groups, which illustrates that the experimental group has better psoriasis treatment effect than the oral group, and the treatment effect is not significantly different from that of the low-dose methotrexate microneedle group, but the experimental group reduces the administration frequency and is more convenient than other groups.
Methotrexate is widely used in the treatment of psoriasis and rheumatoid arthritis as an immunosuppressant and antimetabolite. The methotrexate is coated in the drug carrier and is redistributed to the needle point of the microneedle, and a safer, more stable and more effective drug delivery way is developed through transdermal drug delivery.
It will be understood by those skilled in the art that the foregoing is only a preferred embodiment of the present invention, and is not intended to limit the invention, and that any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (10)
1. The slow release soluble microneedle is characterized by comprising a substrate, a needle body and a carrier which is distributed in the needle body and is coated with a drug to be slow released, wherein the carrier comprises a degradable high molecular material or inorganic nanoparticles modified by a polymer.
2. A microneedle according to claim 1, wherein the inorganic nanoparticles comprise one of a nanocarbon material, gold nanoparticles, quantum dots, magnetic nanoparticles, hollow mesoporous silica, and the polymer is a biodegradable and positively charged polymer.
3. A microneedle according to claim 1, wherein the biodegradable and positively charged polymer is one of chitosan, polydopamine, polyetherimide, poly N, N-dimethylaminoethyl methacrylate.
4. A microneedle according to claim 1, wherein the degradable high molecular material comprises a natural biodegradable high molecular material, a semi-synthetic biodegradable high molecular material or a synthetic biodegradable high molecular material.
5. A microneedle according to claim 4, wherein the natural biodegradable polymer material comprises gelatin, chitosan, sodium alginate, starch or cellulose; the semi-synthetic biodegradable high polymer material comprises carboxymethyl cellulose, methyl cellulose or cellulose acetate; the synthetic biodegradable high molecular material comprises aliphatic polyester polymer, polycarbonate polymer, polyanhydride or poly alpha-amino acid polymer or block polymer.
6. A microneedle according to claim 1, wherein the polymer used for the base and needle body comprises one or more of hyaluronic acid, chondroitin sulfate, sodium alginate, pullulan, hydroxypropyl- β -cyclodextrin, gelatin.
7. The microneedle according to claim 1, wherein the carrier coated with the drug to be sustainedly released has a size of 50 to 5000 nm, and the microneedle contains the drug to be sustainedly released in an amount of 20 to 2000 μ g; the structure of the carrier coated with the drug to be slowly released is one or more of microspheres, microcapsules, nano-particles, liposome, micelle and a slow release film.
8. A method of preparing a microneedle according to any one of claims 1 to 7, comprising the steps of:
(1) preparing a carrier coated with a drug to be slowly released by adopting one of an emulsion method, a dialysis method, a solvent volatilization method, a spray drying method and a polyelectrolyte protection method; the carrier comprises degradable high molecular materials or inorganic nanoparticles;
(2) dissolving or dispersing the carrier coated with the drug to be slowly released in a matrix solution, casting the matrix solution into a mold by a vacuum pumping method, drying and demolding to obtain the slowly released soluble microneedle.
9. The method according to claim 8, wherein the polyelectrolyte protection method is specifically:
dissolving the hollow mesoporous silica nanoparticles and the drug to be slowly released in dimethyl sulfoxide, uniformly stirring, and removing the dimethyl sulfoxide by using a negative pressure method to obtain hollow mesoporous silica nanoparticles loaded with the drug to be slowly released;
dispersing the hollow mesoporous silica nanoparticles loaded with the drug to be slowly released in a biodegradable polymer with positive electricity, stirring, centrifuging and washing to obtain the carrier coated with the drug to be slowly released.
10. Use of sustained-release soluble microneedles according to any one of claims 1-7 for sustained release of methotrexate, wherein the drug to be sustained-released in the microneedles is methotrexate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011539854.9A CN112494421B (en) | 2020-12-23 | 2020-12-23 | Slow-release soluble microneedle, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011539854.9A CN112494421B (en) | 2020-12-23 | 2020-12-23 | Slow-release soluble microneedle, preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112494421A true CN112494421A (en) | 2021-03-16 |
| CN112494421B CN112494421B (en) | 2022-09-20 |
Family
ID=74923188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011539854.9A Active CN112494421B (en) | 2020-12-23 | 2020-12-23 | Slow-release soluble microneedle, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112494421B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113181438A (en) * | 2021-04-26 | 2021-07-30 | 东南大学 | Thermosensitive responsive absorbable orthopedic instrument material capable of self-healing and promoting bone growth and preparation method thereof |
| CN113876743A (en) * | 2021-11-03 | 2022-01-04 | 深圳大学 | Transdermal drug delivery system and preparation method and application thereof |
| CN113876950A (en) * | 2021-11-08 | 2022-01-04 | 浙江大学 | Microneedle patch suitable for NO-synergetic photodynamic therapy and preparation method thereof |
| CN113876948A (en) * | 2021-08-18 | 2022-01-04 | 广州贝奥吉因生物科技股份有限公司 | Germanium alkene two-dimensional nano-drug microneedle, preparation method thereof and microneedle patch |
| CN114099414A (en) * | 2021-11-19 | 2022-03-01 | 烟台魔技纳米科技有限公司 | Microneedle capable of controllably and slowly releasing medicine and preparation method thereof |
| CN114150022A (en) * | 2021-12-06 | 2022-03-08 | 中国科学院精密测量科学与技术创新研究院 | Biochemical molecular cell delivery method based on plant micro-nano structure and application |
| CN114177512A (en) * | 2021-12-20 | 2022-03-15 | 长春工业大学 | Layer-by-layer deposition antibacterial healing-promoting soluble microneedle patch and preparation method thereof |
| CN114432230A (en) * | 2022-02-28 | 2022-05-06 | 浙江工业大学 | Microneedle for treating psoriasis by transdermal delivery of liposome and preparation method thereof |
| CN116463004A (en) * | 2023-04-22 | 2023-07-21 | 西安石油大学 | Preparation method of microcapsule type anti-fouling agent suitable for seawater environment |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010075664A1 (en) * | 2008-12-31 | 2010-07-08 | 江苏大学 | A highly efficient and long-acting slow-release formulation of poorly soluble drugs and preparation method thereof |
| CN103330680A (en) * | 2013-05-31 | 2013-10-02 | 袁伟恩 | Nano drug transdermal preparation and preparation method thereof |
| CN103920153A (en) * | 2014-05-06 | 2014-07-16 | 中国科学院上海硅酸盐研究所 | Chitosan-modified pH responsive medicine-loading controlled release material and preparation method thereof |
| CN103961713A (en) * | 2014-05-06 | 2014-08-06 | 中国科学院上海硅酸盐研究所 | Application of mesoporous silica based controlled release material modified by chitosan |
| CN106492220A (en) * | 2016-11-01 | 2017-03-15 | 东华大学 | There is the preparation method of the mesoporous nano silicon composite aquogel of control-release function |
| CN110200944A (en) * | 2019-07-15 | 2019-09-06 | 蚌埠学院 | A kind of pH/ temperature sensitivity double-response type nano-medicament carrier and its preparation and application |
| CN110812495A (en) * | 2019-12-03 | 2020-02-21 | 东华大学 | Hollow mesoporous silicon-based drug-loaded nanoparticle and preparation and application thereof |
| WO2020043168A1 (en) * | 2018-08-31 | 2020-03-05 | 中科微针（北京）科技有限公司 | Implantable sustained-release microneedle patch and preparation method therefor |
| CN111329832A (en) * | 2020-02-08 | 2020-06-26 | 中山大学 | Nanometer lipid carrier microneedle for treating alopecia and application thereof |
-
2020
- 2020-12-23 CN CN202011539854.9A patent/CN112494421B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010075664A1 (en) * | 2008-12-31 | 2010-07-08 | 江苏大学 | A highly efficient and long-acting slow-release formulation of poorly soluble drugs and preparation method thereof |
| CN103330680A (en) * | 2013-05-31 | 2013-10-02 | 袁伟恩 | Nano drug transdermal preparation and preparation method thereof |
| CN103920153A (en) * | 2014-05-06 | 2014-07-16 | 中国科学院上海硅酸盐研究所 | Chitosan-modified pH responsive medicine-loading controlled release material and preparation method thereof |
| CN103961713A (en) * | 2014-05-06 | 2014-08-06 | 中国科学院上海硅酸盐研究所 | Application of mesoporous silica based controlled release material modified by chitosan |
| CN106492220A (en) * | 2016-11-01 | 2017-03-15 | 东华大学 | There is the preparation method of the mesoporous nano silicon composite aquogel of control-release function |
| WO2020043168A1 (en) * | 2018-08-31 | 2020-03-05 | 中科微针（北京）科技有限公司 | Implantable sustained-release microneedle patch and preparation method therefor |
| CN110200944A (en) * | 2019-07-15 | 2019-09-06 | 蚌埠学院 | A kind of pH/ temperature sensitivity double-response type nano-medicament carrier and its preparation and application |
| CN110812495A (en) * | 2019-12-03 | 2020-02-21 | 东华大学 | Hollow mesoporous silicon-based drug-loaded nanoparticle and preparation and application thereof |
| CN111329832A (en) * | 2020-02-08 | 2020-06-26 | 中山大学 | Nanometer lipid carrier microneedle for treating alopecia and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 孙少平，梁娜: "《高分子材料在纳米给药系统中的应用》", 31 August 2017, 黑龙江大学出版社 * |
| 彭冠杰，郭清泉: "《美白化妆品科学与技术》", 30 June 2019, 中国轻工业出版社 * |
| 许斌: "基于血糖调控微针透皮给药的材料设计与应用", 《中国优秀博硕士学位论文全文数据库(硕士)工程科技Ⅰ辑》 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113181438A (en) * | 2021-04-26 | 2021-07-30 | 东南大学 | Thermosensitive responsive absorbable orthopedic instrument material capable of self-healing and promoting bone growth and preparation method thereof |
| CN113876948A (en) * | 2021-08-18 | 2022-01-04 | 广州贝奥吉因生物科技股份有限公司 | Germanium alkene two-dimensional nano-drug microneedle, preparation method thereof and microneedle patch |
| CN113876743A (en) * | 2021-11-03 | 2022-01-04 | 深圳大学 | Transdermal drug delivery system and preparation method and application thereof |
| CN113876743B (en) * | 2021-11-03 | 2023-12-05 | 深圳大学 | Transdermal drug delivery system and preparation method and application thereof |
| CN113876950A (en) * | 2021-11-08 | 2022-01-04 | 浙江大学 | Microneedle patch suitable for NO-synergetic photodynamic therapy and preparation method thereof |
| CN114099414A (en) * | 2021-11-19 | 2022-03-01 | 烟台魔技纳米科技有限公司 | Microneedle capable of controllably and slowly releasing medicine and preparation method thereof |
| CN114150022B (en) * | 2021-12-06 | 2023-08-22 | 中国科学院精密测量科学与技术创新研究院 | Biochemical molecular cell delivery method based on plant micro-nano structure and application |
| CN114150022A (en) * | 2021-12-06 | 2022-03-08 | 中国科学院精密测量科学与技术创新研究院 | Biochemical molecular cell delivery method based on plant micro-nano structure and application |
| CN114177512A (en) * | 2021-12-20 | 2022-03-15 | 长春工业大学 | Layer-by-layer deposition antibacterial healing-promoting soluble microneedle patch and preparation method thereof |
| CN114177512B (en) * | 2021-12-20 | 2024-04-30 | 长春工业大学 | Antibacterial and healing-promoting soluble microneedle patch deposited layer by layer and preparation method thereof |
| CN114432230A (en) * | 2022-02-28 | 2022-05-06 | 浙江工业大学 | Microneedle for treating psoriasis by transdermal delivery of liposome and preparation method thereof |
| CN114432230B (en) * | 2022-02-28 | 2024-03-22 | 浙江工业大学 | Microneedle for treating psoriasis by percutaneous delivery liposome and preparation method thereof |
| CN116463004A (en) * | 2023-04-22 | 2023-07-21 | 西安石油大学 | Preparation method of microcapsule type anti-fouling agent suitable for seawater environment |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112494421B (en) | 2022-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112494421B (en) | Slow-release soluble microneedle, preparation method and application | |
| Mottaghitalab et al. | Silk fibroin nanoparticle as a novel drug delivery system | |
| Dhanka et al. | Methotrexate loaded gellan gum microparticles for drug delivery | |
| Piotrowicz et al. | Nerve guidance channels as drug delivery vehicles | |
| Dash et al. | Poly-є-caprolactone based formulations for drug delivery and tissue engineering: A review | |
| Campardelli et al. | Supercritical fluids applications in nanomedicine | |
| Ariga et al. | Layer-by-layer self-assembled shells for drug delivery | |
| Jawahar et al. | Polymeric nanoparticles for drug delivery and targeting: A comprehensive review | |
| Wang et al. | Fabrication of drug-loaded biodegradable microcapsules for controlled release by combination of solvent evaporation and layer-by-layer self-assembly | |
| Kulkarni et al. | Synthesis of polymeric nanomaterials for biomedical applications | |
| WO2000064954A1 (en) | Polymeric encapsulation system promoting angiogenesis | |
| Gaydhane et al. | Electrospun nanofibres in drug delivery: advances in controlled release strategies | |
| Guarino et al. | Alginate processing routes to fabricate bioinspired platforms for tissue engineering and drug delivery | |
| Pastorino et al. | Towards the fabrication of polyelectrolyte-based nanocapsules for bio-medical applications | |
| Szabo et al. | Formulation and stability aspects of nanosized solid drug delivery systems | |
| CN105596298B (en) | A kind of PEG-PLGA sustained-release micro-spheres and preparation method thereof containing buprenorphine | |
| Maiti et al. | Cationic polyelectrolyte–biopolymer complex hydrogel particles for drug delivery | |
| KR20170031520A (en) | Porous microspheres with spontaneous pore-closing functionality and method for preparing the same | |
| WO2016089309A1 (en) | Method of preparing hollow microparticles and hollow microparticles prepared thereof | |
| Ortega-Oller et al. | Dual delivery nanosystem for biomolecules. Formulation, characterization, and in vitro release | |
| Yadav et al. | Modulation of physicochemical properties of polymers for effective insulin delivery systems | |
| Thodikayil et al. | Carbohydrate-Based Biodegradable Polymers for Biomedical Applications | |
| Pacho et al. | Synthesis of micro-and nanoparticles of alginate and chitosan for controlled release of drugs | |
| CN112245409B (en) | Vegetable protein-ursodesoxycholic acid sustained-release nanoparticle composite microcapsule and preparation method thereof | |
| Kulamarva et al. | Microcapsule carbon nanotube devices for therapeutic applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |